Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David C. Burns who wrote (3278)	6/10/1999 8:59:00 PM
From: Thomas M.	Read Replies (1) \| Respond to of 10280

<<< Reuters reported recently that Sepracor received a letter from the Food and Drug Administration regarding Sepracor's asthma drug, Xopenex, in which the FDA chided the company for misleading statements on safety and efficacy in its promotional materials. "It is relatively normal for companies to get these letters, and in fact, a lot of companies will expect to get them," Southwell said. Sepracor responded to the issues raised in the first letter, and the FDA replied, saying they now "considered the matter closed," he said. >>> biz.yahoo.com